A brief review on recent developments in animal models of schizophrenia

Indian Journal of Pharmacology

Volumn 43, Issue 4, 2011, Pages 375-380

  Trivedi, M S ^a   Jarbe, T ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Animal models; dopamine; face validity; glutamate; predictive validity; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ARIPIPRAZOLE; CLOZAPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; GLUTATHIONE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEU DIFFERENTIATION FACTOR; NEUROTRANSMITTER; OLANZAPINE; PICROTOXIN; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; ZIPRASIDONE;

COGNITION; COGNITIVE DEFECT; CONSTRUCTIVE VALIDITY; DENDRITIC SPINE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; EPIDEMIOLOGICAL DATA; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; EYELID REFLEX; FACE VALIDITY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; LATENT INHIBITION; MENTAL PATIENT; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTIVE VALIDITY; PREPULSE INHIBITION; PSYCHOLOGICAL WELL BEING; PSYCHOPHARMACOTHERAPY; PSYCHOPHYSIOLOGY; RECEPTOR AFFINITY; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SENSORY GATING; SINGLE NUCLEOTIDE POLYMORPHISM; SOCIAL INTERACTION; SYNAPSE; VALIDITY;

EID: 80053256379     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.83104     Document Type: Review

References (35)

1. Kilts CD. The changing roles and targets for animal models of Schizophrenia. Biol Psychiatry 2001;50:845-55. (Pubitemid 34020698)
2. Cowan WM, Harter DH, Kandel ER. The emergence of modern neuroscience: Some implications for neurology and psychiatry. Annu Rev Neurosci 2000;23:343-91. (Pubitemid 30350047)
3. Kendler KS, Diehl SR. The genetics of schizophrenia: A current, geneticepidemiologic perspective. Schizophr Bull 1993;19:261-85. (Pubitemid 23183148)
4. Maier W. Common risk genes for affective and schizophrenic psychoses. Eur Arch Psychiatry Clin Neurosci 2008;258:37-40. (Pubitemid 351758759)
5. Davidson L, McGlashan TH. The varied outcomes of schizophrenia. Can J Psychiatry 1997;42:34-43. (Pubitemid 27141614)
6. Gold JM, Hermann BP, Randolph C, Wyler AR, Goldberg TE, Weinberger DR. Schizophrenia and temporal lobe epilepsy: A neuropsychological analysis. Arch Gen Psychiatry 1994;5:265-72. (Pubitemid 24127298)
7. Marcotte ER, Pearson DM, Srivastava LK. Animal models of schizophrenia: A critical review. J Psychiatry Neurosci 2001;26:395-410. (Pubitemid 34082728)
8. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 2005;10:40-68. (Pubitemid 40139588)
9. Kirov G, O'Donovan MC, Owen MJ. Finding schizophrenia genes. J Clin Invest 2005;115:1440-8. (Pubitemid 40814648)
10. Heydebrand G. Cognitive deficits in the families of patients with schizophrenia. Curr Opin Psychiatry 2006;19:277-81. (Pubitemid 44309485)
11. Jober R. Genetics of Schizophrenia: Form animal models to clinical studies. J Psychiatr Neurosci 2002;27:336-47.
12. Bellon A. New genes associated with Schizophrenia in neurite formation: A review of cell culture experiments. Mol Psychiatry 2007;12:620-9. (Pubitemid 46998253)
13. Flensmark J. Is there an association between the use of heeled footwear and schizophrenia? Med Hypotheses 2004;63:740-7. (Pubitemid 39485849)
14. Mittal VA, Ellman LM, Cannon TD. Gene-environment interaction and covariation in schizophrenia: The role of obstetric complications. Schizophr Bull 2008;34:1083-94.
15. Beckmann H. Developmental malformations in cerebral structures of schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1999;249:44-7.
16. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: From pathophysiology to treatment. Ann N Y Acad Sci 2003;1003:138-58. (Pubitemid 38083052)
17. Castagne V, Rougemont M, Cuenod M, Do KQ. Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: Relevance to schizophrenia. Neurobiol Dis 2004;15:93-105. (Pubitemid 38134384)
18. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology (Berl) 2003;169:215-33. (Pubitemid 37264943)
19. Hetem LA, Danion JM, Diemunsch P, Brandt C. Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology (Berl) 2000;152:283-8.
20. Goff DC, Freudenreich O, Evins AE, Augmentation strategies in the treatment of schizophrenia. CNS Spectr 2001;6:904,907-11.
21. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1:133-52. (Pubitemid 17119661)
22. Dworkin RH, Opler LA. Simple schizophrenia: Negative symptoms and prefrontal hypodopaminergia. Am J Psychiatry 1992;149:1284-5.
23. Abi Dargham A. Increased striatal dopamine transmisison in shcizophreniaL confirmation in a second cohort. Am J Psychiatry 1998;155:761-7.
24. Laruelle M. Imaging dopamine transmission in schizophrenia: A review and meta-analysis. Q J Nucl Med 1998;42:211-21. (Pubitemid 28529874)
25. Hartman DS, Civelli O. Dopamine receptor diversity: Molecular andpharmacological perspectives. Prog Drug Res 1997;48:173-94. (Pubitemid 27242829)
26. Jentsch JD, Redmond DE Jr, Elsworth JD, Taylor JR, Youngren KD, Roth RH. Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science 1997;277:953-5. (Pubitemid 27366680)
27. French ED, Vantini G. Phencyclidine-induced locomotor activity in the rat is blocked by 6-hydroxydopamine lesion of the nucleus accumbens: Comparisons to other psychomotor stimulants. Psychopharmacology (Berl) 1984;8:83-8. (Pubitemid 14222290)
28. Burnet PW, Eastwood SL, Harrison PJ. [3H] WAY-100635 for 5-HT1A receptor autoradiography in human brain: A comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 1997;30:565-74. (Pubitemid 27187227)
29. Gleason SD, Shannon HE. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl) 1997;129:79-84. (Pubitemid 27037454)
30. Japha K, Koch M. Picrotoxin in the medial prefrontal cortex impairs sensorimotor gating in rats: Reversal by haloperidol. Psychopharmacology (Berl) 1999;144:347-54. (Pubitemid 29307259)
31. Lewis DA, Pierri JN, Volk DW, Melchitzky DS, Woo TU. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry 1999;46:616-26. (Pubitemid 29401859)
32. Lewis D. GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia. Brain Res Rev 2000;31:27-36.
33. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Tamminga C, Wood F. Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch Gen Psychiatry 1993;50:825-31. (Pubitemid 23303104)
34. Murray RM, O'Callaghan E, Castle DJ, Lewis SW. A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull 1992;18:319-32.
35. Roberts G. Schizophrenia: A neuropathological perspective. Br J Psychiatry 1991;158:8-17.